[go: up one dir, main page]

MD4349B1 - N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation - Google Patents

N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation Download PDF

Info

Publication number
MD4349B1
MD4349B1 MDA20140062A MD20140062A MD4349B1 MD 4349 B1 MD4349 B1 MD 4349B1 MD A20140062 A MDA20140062 A MD A20140062A MD 20140062 A MD20140062 A MD 20140062A MD 4349 B1 MD4349 B1 MD 4349B1
Authority
MD
Moldova
Prior art keywords
human melanoma
compound
hydrazinecarbothioamide
ylmethylene
mew
Prior art date
Application number
MDA20140062A
Other languages
Romanian (ro)
Russian (ru)
Other versions
MD4349C1 (en
Inventor
Aurelian Gulea
Andrzej Lipkowski
Olga Garbuz
Joanna MATALINSKA
Victor Ţapcov
Original Assignee
Universitatea De Stat Din Moldova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitatea De Stat Din Moldova filed Critical Universitatea De Stat Din Moldova
Priority to MDA20140062A priority Critical patent/MD4349C1/en
Publication of MD4349B1 publication Critical patent/MD4349B1/en
Publication of MD4349C1 publication Critical patent/MD4349C1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

The invention relates to chemistry and medicine, namely to an organic compound from the class of thioamides, which may find application in medicine as a cytostatic agent for the prophylaxis and treatment of human melanoma.Summary of the invention consists in the synthesis of N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound of formula:,exhibiting the human melanoma MeW-164 cell proliferation inhibition property.
MDA20140062A 2014-06-23 2014-06-23 N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation MD4349C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDA20140062A MD4349C1 (en) 2014-06-23 2014-06-23 N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDA20140062A MD4349C1 (en) 2014-06-23 2014-06-23 N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation

Publications (2)

Publication Number Publication Date
MD4349B1 true MD4349B1 (en) 2015-05-31
MD4349C1 MD4349C1 (en) 2015-12-31

Family

ID=53190461

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20140062A MD4349C1 (en) 2014-06-23 2014-06-23 N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation

Country Status (1)

Country Link
MD (1) MD4349C1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4520B1 (en) * 2016-12-16 2017-10-31 Государственный Университет Молд0 N-(4-butoxyphenyl)-2-(pyridin-2-ylmethylidene)hydrazinecarbothioamide as T-47D breast cancer cells growth inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5281715A (en) * 1992-05-13 1994-01-25 Yale University 2-formylpyridine thiosemicarbazone compounds
CN102210698A (en) * 2004-01-02 2011-10-12 维奥恩药品公司 Use of composition containing 3-aminopyridine-2-formaldehyde thiosemicarbazone in treatment of cancers
CN101260121A (en) * 2007-03-07 2008-09-10 卡南吉医药科技（上海）有限公司 Complex compound of heteroaromatic thiosemicarbazone and transition metal, and application thereof in preparing antineoplastic medicine
MD3655G2 (en) * 2007-09-03 2009-02-28 Государственный Университет Молд0 Inhibitor of human myeloid leukemia on base of bis(2-hydroxy-8-phenyl-tricyclo/7.3.1.0.2,7/-tridecane-13-on-thiosemicarbazonato)copper
MD3771G2 (en) * 2008-04-30 2009-07-31 Государственный Университет Молд0 Inhibitors of 17β-HSD enzyme, stimulator for prostate cancer cell multiplication
WO2010006438A1 (en) * 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
MD3890G2 (en) * 2008-09-08 2009-12-31 Государственный Университет Молд0 Inhibitors of human myeloid leukemia on base of coordinative compounds of copper(II) with salicylidene thiocarbazides
MD3995C2 (en) * 2009-05-11 2010-07-31 Государственный Университет Молд0 Use of di(m-Ophenoxy)-di{[2-(4-aminobenzenesulfamido)-5-ethyl-1,3,4-thiadiazole]-3,5-dibromosalicylidenethiosemicarbazonato(-1)-copper} as inhibitor of mammary cancer T-47D cell proliferation
MD3996C2 (en) * 2009-05-25 2010-07-31 Государственный Университет Молд0 Perchlorates of 5-R-salicylidene-4-phenylthiosemicarbazonato(1-)-aquacopper(II) possessing properties of inhibitors of 17b-HSD enzyme activity (type 1)
MD4190C1 (en) * 2011-06-16 2013-07-31 Государственный Университет Молд0 Inhibitor of human myeloid leukemia based on {bis[2-(3,5-dibrom-2-hydroxyphenyl)-2-oxoethyl-piperidin-1-carbodithioato(1-)-O,O′]copper}
MD4215C1 (en) * 2012-07-09 2013-11-30 Государственный Университет Молд0 Inhibitor of human myeloid leukemia based on N-(4-(5-(pyridin-2-yl)-4,5-dihydro-1H-pyrazol-3-yl)phenyl)-2-(pyridin-2-ylmethylen)-hydrazinecarbothioamide

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD4520B1 (en) * 2016-12-16 2017-10-31 Государственный Университет Молд0 N-(4-butoxyphenyl)-2-(pyridin-2-ylmethylidene)hydrazinecarbothioamide as T-47D breast cancer cells growth inhibitor

Also Published As

Publication number Publication date
MD4349C1 (en) 2015-12-31

Similar Documents

Publication Publication Date Title
PH12016501972B1 (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12017502141A1 (en) Compounds and their methods of use
EA201792205A1 (en) HETEROCYCLIC COMPOUNDS AS LSD1 INHIBITORS
PH12017501669A1 (en) Alpha-cinnamide compounds and compositions as hdac8 inhibitors
PH12017500509A1 (en) Benzyl substituted indazoles as bub1 inhibitors
TW201613911A (en) Heterocyclic compounds and uses thereof
MX2017004200A (en) Heteroaryl compounds as btk inhibitors and uses thereof.
CL2014002873A1 (en) Compounds derived from pyrimidin-amine or triazin-amine, adn-pk inhibitors; pharmaceutical composition; and its use for the treatment of cancer.
MX378194B (en) Organic compounds
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
MX2016002794A (en) Antiproliferative compounds.
PH12016501462A1 (en) Neprilysin inhibitors
PH12016502130A1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX373320B (en) PDE2 INHIBITOR COMPOUNDS.
BR112017000730A2 (en) pyrrolidinone derivatives as metap-2 inhibitors
MX370412B (en) Antimycotic compound.
MX362896B (en) Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer.
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
MX2015016332A (en) Pyrrolotriazines as alk inhibitors.
EA201270728A1 (en) PURINE CONNECTIONS
CL2017002229A1 (en) Bace1 inhibitors.
MX371158B (en) Organic compounds.
MD4349B1 (en) N-(3-methoxyphenyl)-2-(pyridine-2-ylmethylene)-hydrazinecarbothioamide compound - inhibitor of human melanoma MeW-164 cell proliferation
EA201270727A1 (en) PURINE CONNECTIONS

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees